Psj Biochem Diagnostic Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 24-10-2024
- Paid Up Capital ₹ 0.10 M
as on 24-10-2024
- Company Age 18 Year, 3 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 9.10 M
as on 24-10-2024
- Revenue -59.29%
(FY 2023)
- Profit -75.61%
(FY 2023)
- Ebitda -6.60%
(FY 2023)
- Net Worth 5.87%
(FY 2023)
- Total Assets 7.15%
(FY 2023)
About Psj Biochem Diagnostic
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹9.10 M.
Indu Tyagi and Gunjan Tyagi serve as directors at the Company.
- CIN/LLPIN
U85195DL2006PTC152508
- Company No.
152508
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
26 Aug 2006
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Psj Biochem Diagnostic Private Limited offer?
Psj Biochem Diagnostic Private Limited offers a wide range of products and services, including Indoor Lights & Lighting Accessories, Miniature Bulbs, Medical Laboratory Instruments, IVDs & Analyzers, Office Automation Products & Devices, Projector Parts & Peripherals, Clinical Reagents, Hematology Analyzers, Biochemistry Analyzer, Decorative Light, Lamp & Lamp Shades.
Who are the key members and board of directors at Psj Biochem Diagnostic?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Indu Tyagi  | Director | 16-Aug-2011 | Current |
| Gunjan Tyagi | Director | 05-Jul-2021 | Current |
Financial Performance of Psj Biochem Diagnostic.
Psj Biochem Diagnostic Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 59.29% decrease. The company also saw a substantial fall in profitability, with a 75.61% decrease in profit. The company's net worth moved up by a moderate rise of 5.87%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Psj Biochem Diagnostic?
In 2023, Psj Biochem Diagnostic had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 29 Mar 2022 | ₹9.10 M | Open |
How Many Employees Work at Psj Biochem Diagnostic?
Unlock and access historical data on people associated with Psj Biochem Diagnostic, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Psj Biochem Diagnostic, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Psj Biochem Diagnostic's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
